Correlation between multi-drug resisitance and Her-2 gene in breast cancer
- Author:
- No author available
- Journal Title:
- Cancer Research and Clinic
- Issue:
- 4
- DOI:
- 10.3760/cma.j.issn.1006-9801.2012.04.005
- Key Word:
- 乳腺肿瘤;多药耐药相关蛋白质类;基因,erbB-2;原位杂交荧光;免疫组织化学;Breast neoplasms;Multidrug resistance-associated proteins;Genes,erbB-2;In situ hybridization,fluorescence;Immunohistochemistry
Abstract： Objective To investigate the correlation between the expression of p170、GST-π 、TOPO Ⅱ and the expression of Her-2 in human breast cancer. Methods The expression of Her-2 was detected by fluorescence in situ hybridization.The expression of p170,GST-π,TOPO Ⅱ were tested in 48 breast cancer by immunohistochemical SP method,and their correlations with clinicopathological features and the expression of Her-2 were analyzed.Results The positive rate of p170,GST-π,TOPO Ⅱ were 43.8 ％(21/48),39.6 ％(19/48),56.3 ％(27/48),respectively. The expression of p170, GST-π,TOPO Ⅱ positively correlated with the expression of Her-2(P＜ 0.05).The levels of p170,GST-π,TOPO Ⅱ expression were not associated with age,primary tumor and lymph node metastasis(P ＞ 0.05).Conclusion There is great possibility of chemotherapy drug resistance in breast cancer with expression of Her-2.Expressions of p170,GST-π,TOPO Ⅱ and Her-2 have an instructive significance for chemotherapy.
- [1]位嘉,刘芳芳,付丽.拓扑异构酶Ⅱα在乳腺癌中的研究现状[J].2008,(2).
- [2]丁渭,郑春艳,贺智敏,等.HER2介导乳腺癌细胞多药耐药的作用及机制[J].2005,(5).
- [3]陈亦欣,陈伟,王秀清,等.乳腺癌组织中MDR1,TOPOⅡ和C-erbB-2的表达及其相互关系[J].2003,(16).
- [4]李杰,许良中,吴炅.三种耐药基因蛋白表达在乳腺癌中的临床意义[J].2001,(8).
- [5]麦国丰,罗荣城,马树东,等.HER2表达与乳腺癌预后的相关性研究[J].2003,(10).
- [6]孙浩,于晓东.P-gp、GST-π和C-erbB-2在乳腺癌中的表达及其临床意义[J].2009,(1).
- [7]B J, Trock,F, Leonessa,R, Clarke.Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.[J].1997,89.
- [8]C O, Bellamy,D J, Harrison.Evaluation of glutathione S-transferase Pi in non-invasive ductal carcinoma of breast.[J].1994,69.
- [9]Hyun Cheol Chung,Sun Young Rha,Joo Hang Kim,etc.P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer[J].1997,42(1).